NeueHealth (NEUE) Q2 2024 earnings summary

Executive summary

• Q2 2024 delivered solid results with positive Adjusted EBITDA, advancing a value-driven, consumer-centric care model and expanding partnerships, though revenue was slightly below expectations due to seasonality.

• Net loss for Q2 2024 was $57.7 million, reflecting ongoing restructuring and business model shifts.

• Secured a new $150 million term loan facility with Hercules Capital in June 2024, strengthening the capital position.

• Served over 470,000 consumers across ACA marketplace, Medicare, and Medicaid in Q2 2024.

• Management acknowledges substantial doubt about the ability to continue as a going concern due to ongoing losses and liquidity constraints.

Financial highlights

• Q2 2024 consolidated revenue was $226 million, down from $298 million in Q2 2023; gross margin improved to $48.3 million (21.4%).

• Adjusted EBITDA for Q2 2024 was $4 million (1.8% margin), positive for the second consecutive quarter.

• Net loss for Q2 2024 was $57.7 million; basic and diluted loss per share was $(8.65).

• Six-month revenue was $471.1 million, with adjusted EBITDA of $7.6 million and net loss of $61.9 million.

• Medical costs decreased 27.5% year-over-year in Q2 2024, primarily due to fewer ACO REACH beneficiaries.

Outlook and guidance

• Reaffirmed full-year 2024 Adjusted EBITDA guidance of $15–$25 million and revenue of approximately $950 million.

• NeueCare segment revenue forecast at $320 million; NeueSolutions at $640 million.

• Anticipate serving 475,000–500,000 consumers in 2024, with expectations to reach the high end of the range.

• Adjusted operating cost ratio expected to be 15%–16% (excluding corporate costs), or 19%–20% including corporate costs.

• Management is focused on driving positive operating cash flow and accessing additional liquidity, but warns that existing cash and investments are insufficient for the next 12 months.